comparemela.com

Latest Breaking News On - Quarter for fennec pharmaceuticals - Page 4 : comparemela.com

Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $18,693.29 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC – Free Report) Director Chris A. Rallis sold 2,207 shares of the business’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $8.47, for a total value of $18,693.29. Following the completion of the transaction, the director now owns 28,826 shares in the […]

United-states
America
Chrisa-rallis
Jpmorgan-chase-co
News-ratings-for-fennec-pharmaceuticals-daily
Securities-exchange-commission
Quarter-for-fennec-pharmaceuticals
Institutional-trading-of-fennec-pharmaceuticals
Fennec-pharmaceuticals
Barclays-plc
Fennec-pharmaceuticals-inc

Chris A. Rallis Sells 2,207 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC – Free Report) Director Chris A. Rallis sold 2,207 shares of the firm’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $8.47, for a total transaction of $18,693.29. Following the completion of the transaction, the director now owns 28,826 shares in the […]

United-states
Chrisa-rallis
Solas-capital-management
Fennec-pharmaceuticals-trading
Opaleye-management-inc
Fennec-pharmaceuticals-inc
News-ratings-for-fennec-pharmaceuticals-daily
Harbert-fund-advisors-inc
Cantor-fitzgerald
Quarter-for-fennec-pharmaceuticals
Fennec-pharmaceuticals

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $18,693.29 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC – Free Report) Director Chris A. Rallis sold 2,207 shares of the firm’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $8.47, for a total value of $18,693.29. Following the sale, the director now directly owns 28,826 shares in the company, valued […]

United-states
America
Chrisa-rallis
Quarter-for-fennec-pharmaceuticals
Securities-exchange-commission
Jpmorgan-chase-co
Boothbay-fund-management
Fennec-pharmaceuticals
Barclays-plc
Cantor-fitzgerald
Fennec-pharmaceuticals-inc

Opaleye Management Inc. Acquires New Position in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Opaleye Management Inc. bought a new position in Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) in the fourth quarter, Holdings Channel.com reports. The firm bought 272,200 shares of the company’s stock, valued at approximately $2,613,000. Other institutional investors also recently bought and sold shares of the company. UBS Group AG grew its stake in shares […]

United-states
Fennec-pharmaceuticals-price-performance
News-ratings-for-fennec-pharmaceuticals-daily
Fennec-pharmaceuticals
Quarter-for-fennec-pharmaceuticals
Fennec-pharmaceuticals-inc
Jpmorgan-chase-co
Citigroup-inc
Holdings-channel
Opaleye-management-inc
Cantor-fitzgerald

Millennium Management LLC Has $2.43 Million Stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Millennium Management LLC decreased its holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) by 36.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 257,621 shares of the company’s stock after selling 147,151 shares during the period. Millennium Management LLC owned about 0.99% […]

United-states
Craig-hallum
Morgan-stanley
Geode-capital-management
Fennec-pharmaceuticals
Fennec-pharmaceuticals-inc
Zacks-investment-research
Fennec-pharmaceuticals-profile-get-rating
Renaissance-technologies
Exchange-commission
Maxim-group
Cantor-fitzgerald

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.